ERNA
Ernexa Therapeutics Inc (ERNA)
Healthcare • NASDAQ • $7.53-3.71%
- Symbol
- ERNA
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $7.53
- Daily Change
- -3.71%
- Market Cap
- $8.78M
- Trailing P/E
- N/A
- Forward P/E
- -0.78
- 52W High
- $101.25
- 52W Low
- $3.18
- Analyst Target
- N/A
- Dividend Yield
- N/A
- Beta
- 1.89
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Company websiteResearch ERNA on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.